The antipsychotic drug, olanzapine, one of the most widely used drugs in clinical medicine,
has a high rate of discontinuation due to inefficacy and/or adverse effects. We identified a …

Psychiatric pharmacotherapy with olanzapine is commonplace. We investigated the
influence of CYP1A2* 1F (− 163A, rs762551) and serotonergic polymorphisms on …

Genetic variation in cytochrome enzymes is known to affect drug metabolism and influence
treatment response. Recently, the rs472660 variant in CYP3A43 has been associated with …

Olanzapine is an atypical antipsychotic widely used for the treatment of schizophrenia,
which often causes serious adverse drug reactions. Currently, there are no clinical …

Olanzapine is a commonly prescribed atypical antipsychotic agent for treatment of patients
with schizophrenia and bipolar disorders. Previous in vitro studies using human liver …

Objective Metabolism of the atypical antipsychotic olanzapine (OLA) is partially catalyzed by
cytochrome P450 (CYP) 1A2, a target of aryl hydrocarbon receptor (AHR)-mediated …

The pharmacokinetics of the atypical antipsychotic, olanzapine, display large interindividual
variation leading to multiple-fold differences in drug exposure between patients at a given …

Background: Although several polymorphisms in olanzapine-metabolizing enzymes have
been identified, the clear role and benefit for pharmacotherapy remain uncertain. The aim of …

Introduction: Schizophrenia, a mental disorder, is a debilitating condition which typically
strikes young people in their early 20's. Antipsychotic medications are widely prescribed for …

Objective To determine the impact of CYP1A2 genetic polymorphisms on the
pharmacokinetics of CYP1A2‐metabolized antipsychotic drugs in humans by means of …